Gajewski T, Flickinger S. 2000. A Phase II study of outpatient chemoimmunotherapy using cisplatin and DTIC followed by GM-CSF, IL-2, and IFN-alpha-2b in patients with metastatic melanoma. Proc Am Soc Clin Oncol, 19:(abstr 2271). Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. 2001. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutrope- nia: a multicenter randomized trial. J Natl Cancer Inst, 93:31–38. Gasparetto C, Gasparetto M, Morse M, et al. 2002. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-ligand and G-CSF or GM-CSF. Cytokine, 18:8–19. Gaudernack G, Gjertsen MK. 1999. Combination of GM-CSF with antitu- mour vaccine strategies. Eur J Cancer, 35:S33–5. Gazitt Y, Akay C, Thomas C 3rd. 2006. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin’s lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev, 15:269–77. Gibbs P, O`Day S, Richards J, et al. 2000. A multicenter phase ii study of modiﬁed biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSF. Proc Am Soc Clin Oncol (abstr 2255), 19. Gilliet M, Liu YJ. 2002. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med, 195:695–704. Groenewegen G, Bloem A, De Gast GC. 2002. Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony- stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother, 51:630–6. Groenewegen G, De Gast GC. 1999. GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy. Eur J Cancer, 35(Suppl 3):S23–4. Grouard G, Rissoan MC, Filgueira L, et al. 1997. The enigmatic plasma- cytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med, 185:1101–11. Hart DN. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 90:3245–87. Hersey P, Menzies SW, Halliday GM, et al. 2004. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother, 53:125–34. Hersh EM, Stopeck AT. 1997. Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res, 3:2623–9. Hoption Cann SA, Van Netten JP, Van Netten C, et al. 2002. Spontane- ous regression: a hidden treasure buried in time. Med Hypotheses, 58:115–19. Hotton KM, Khorsand M, Hank JA, et al. 2000. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer, 88:1892–901. Hsu FJ, Benike C, Fagnoni F, et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med, 2:52–8. Hung K, Hayashi R, Lafond-Walker A, et al. 1998. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med, 188:2357–68. Inaba K, Inaba M, Romani N, et al. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med, 176:1693–702. Jaffee EM, Hruban RH, Biedrzycki B, et al. 2001. Novel allogeneic granu- locyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol, 19:145–56. Janik JE, Miller LL, Korn EL, et al. 2001. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood, 97:1942–6. Biologics:Targets & Therapy 2008:2(1) Clinical uses of GM-CSF Kadowaki N, Ho S, Antonenko S, et al. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to dif- ferent microbial antigens. J Exp Med, 194:863–9. Keilholz U, Weber J, Finke JH, et al. 2002. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother, 25:97–138. Kessinger A, Armitage JO, Landmark JD, et al. 1986. Reconstitution of human hematopoietic function with autologous cryopreserved circulat- ing stem cells. Exp Hematol, 14:192–6. Kolb HJ, Rank A, Chen X, et al. 2004. In-vivo generation of leukaemia- derived dendritic cells. Best Pract Res Clin Haematol, 17:439–51. Korbling M, Anderlini P. 2001. Peripheral blood stem cell versus bone mar- row allotransplantation: does the source of hematopoietic stem cells matter? Blood, 98:2900–8. Korbling M, Burke P, Braine H, et al. 1981. Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol, 9:684–90. Kusumoto M, Umeda S, Ikubo A, et al. 2001. Phase 1 clinical trial of irradi- ated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother, 50:373–81. Kuwana M, Kaburaki J, Wright TM, et al. 2001. Induction of antigen-speciﬁc human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol, 31:2547–57. Larsson M, Fonteneau JF, Bhardwaj N. 2003. Cross-presentation of cell- associated antigens by dendritic cells. Curr Top Microbiol Immunol, 276:261–75. Leong SP, Enders-Zohr P, Zhou YM, et al. 1999. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother, 22:166–74. Levine AM, Reed JA, Kurak KE, et al. 1999. GM-CSF-deﬁcient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest, 103:563–9. Li JM, Waller EK. 2004. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow trans- plantation. Biol Blood Marrow Transplant, 10:540–51. Lieschke GJ, Grail D, Hodgson G, et al. 1994. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deﬁciency, and impaired neutrophil mobi- lization. Blood, 84:1737–46. Lissoni P, Mengo S, Bucovec R, et al. 2003. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients. In Vivo, 17:73–5. Lonial S, Hicks M, Rosenthal H, et al. 2004. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony- stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant, 10:848–57. Lonial S, Mcmillan S, Torre C, et al. 2006. A randomized trial to evaluate the impact of cytokines (G-CSF or GM + G-CSF) on dendritic cell and T-cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant. Blood, 108:(abstr 3377). Lutzky J, Blaustein A, Weingrad D, et al. 2003. Phase I/II study of GM-CSF and thalidomide in patients with high-risk malignant melanoma. Proc Am Soc Clin Oncol, 22:(abstr 2916). Masucci G, Ragnhammar P, Wersall P, et al. 1990. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother, 31:231–5. Matzinger P. 1994. Tolerance, Danger, and the Extended Family. Ann Rev Immunol, 12:991–1045. Metcalf D. 1998. Cell-cell signalling in the regulation of blood cell forma- tion and function. Immunol Cell Biol, 76:441–7. Metcalf D, Nicola NA. 1995. The hematopoietic colony stimulating factors. New York, NY: Cambridge University Press. 25